Co., Inc. (NYSE:MRK), a global healthcare leader, faces a complex landscape of opportunities and challenges as it navigates the competitive biopharmaceutical industry. This comprehensive analysis ...

Merck & Co. Inc. closed 29.03% below its 52-week high of $134.63, which the company reached on June 25th.

Couch co-op and split-screen tend to be associated with consoles as the terms conjure images of friends playing Mario Party and Crash Team Racing on a TV, but PC owners have plenty of options as well.

With a market cap of $252.6 billion, Rahway, New Jersey-based Merck & Co., Inc. (MRK) is a global leader in the healthcare industry, operating through its Pharmaceutical and Animal Health segments.

WuXi Vaccines, a wholly-owned subsidiary of China’s contract development and manufacturing organization (CDMO) WuXi Biologics (HKEX: 2269), today announced a definitive agreement with Merck & Co’s ...

The FDA has approved a new triple-drug antibiotic from Merck & Co, but the company and regulator have cautioned it should only be prescribed for last-ditch use. Recarbrio – which based on ...

Bearish flow noted in Merck (MRK) with 11,740 puts trading, or 3x expected. Most active are Feb-25 95 puts and Jan-25 100 calls, with total volume in those strikes near 11,400 contracts.

Last Friday, the Medicines and Healthcare Products Regulatory Agency approved Merck & Co Inc’s MRK Winrevair (sotatercept) for adult patients with pulmonary arterial hypertension (PAH).

In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other pharma dividend stocks. The pharmaceutical industry in 2024 faced a relatively quiet ...